Table 2.

Potential telomere length modulators in tumor prevention

NO	Compounds	Level	Preclinical Model	Mechanism	Efficacy/Progress
1	TA65	Preclinical	Multiple cells	a. Extended the average telomere length of leukocytes b. Increased cytotoxic T cells	Help the body to reinforce the immune system.
2	CAG	Preclinical	Multiple cells	a. accelerates the presentation of tumor antigens b. The combination of CAG and PD-1 antibody can also effectively enhance the killing ability of CD8+T cells	Anti-cancer
3	Vc	Preclinical	Multiple cancer cells	a. Reduce telomerase activity in HeLa cells by restoring cell redox potential, inhibiting E6 gene and promoting p53 gene expression b. Target redox imbalances, epigenetic reprogramming, and oxygen-sensing regulation in cancer cells	a. Activate telomerase in HeLa cells b. Treat and prevent cancer